ClinicoEconomics and Outcomes Research最新文献

{"title":"Exploring Psychosocial and Economic Support for Children with HIV/AIDS: Perspectives of Health and Community Workers in the Katuba Health Zone, Lubumbashi.","authors":"Chadrack Kabeya Diyoka, Fanny Malonga Kaj, Laetitia Ngongo Mwanvua, Michael Mika Mukanya, Patrick Kazadi Bukasa, Ghyslain Ngongo Lambo, Criss Koba Mjumbe","doi":"10.2147/CEOR.S526529","DOIUrl":"10.2147/CEOR.S526529","url":null,"abstract":"<p><strong>Objective: </strong>To determine the challenges requiring psychosocial and economic support faced by children living with HIV, to describe the interventions in place and to explore the experience of professionals providing services in a health district in the city of Lubumbashi in the DRC.</p><p><strong>Methods: </strong>A descriptive case study using the phenomenological qualitative approach was conducted in the Katuba health district. Over the course of eight months (June 1, 2024 - February 8, 2025), with data collection from July 1 and August 1, 2024. HIV focal points participated in in-depth, semi-structured interviews, and case managers participated in focus groups. ATLAS.ti (version 12) was used to conduct the thematic analysis.</p><p><strong>Results: </strong>On average, the participants had 15.5 ± 11.43 years of experience, and 50% were senior nurses. The average age of the sample was 44.21 ± 9.40 years, and 57% of participants were female. Significant obstacles included the daily stresses of therapy, difficulties with adherence (especially when symptoms were not obvious), and experiences of discrimination, stigma, and exclusion within families, schools, and wider society. These issues adversely impacted education, work, and interpersonal connections. Children people also experienced financial difficulties, limited access to job opportunities and vocational training, and anxiety about an uncertain future. While psychosocial support was universally accepted, economic assistance was considered only partially beneficial due to funding delays and resource limitations. The recommendations focused on increasing government financing, improving access to medical and emotional support services, raising awareness of prevention measures, and strengthening human and material resources.</p><p><strong>Conclusion: </strong>This research highlights the challenges faced by children living with HIV and underlines the importance of early identification and effective management of these problems to improve their quality of life. Current interventions are deemed effective, but could be improved by strengthening the support system, particularly in terms of human and organisational resources.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"17 ","pages":"547-559"},"PeriodicalIF":2.2,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12380006/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144973629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends, Patient Outcomes, and Resource Utilization Associated with Surgical Staplers During Robotic Sleeve Gastrectomy.","authors":"I-Wen Pan, Zasim Azhar Siddiqui","doi":"10.2147/CEOR.S525137","DOIUrl":"10.2147/CEOR.S525137","url":null,"abstract":"<p><strong>Purpose: </strong>Robotic platforms are commonly used for sleeve gastrectomy, despite the high capital costs and little understanding of the roles of platform-specific consumables and standard surgical alternatives in clinical outcomes and healthcare resource utilization. This study evaluates the trend, the effectiveness (outcomes) and efficiency (resource utilization) of different types of surgical staplers used in robotic sleeve gastrectomy (RSG).</p><p><strong>Patients and methods: </strong>This was a retrospective observational cohort study analyzing data from the PINC AI™ Healthcare Data database. Patients were included if they underwent elective, inpatient, primary sleeve gastrectomy performed using the Intuitive Surgical robotic system (Sunnyvale, CA) with either a bedside stapler (BS, Signia™, Endo-GIA™, or Tri-staple™) or a robotic stapler (RS, Sureform™). The primary outcome measures included inpatient costs, complications, operating room time (ORT), length of stay (LOS), and intensive care unit visits. Outcomes were analyzed using bivariate analyses, multivariable generalized linear models (GLM), and propensity-score matching (PSM).</p><p><strong>Results: </strong>Of 18,892 total RSG procedures that met eligibility criteria, robotic staplers were used in 15,152 procedures (80.2%) and bedside staplers were used in 3740 (19.8%). While RSG increased dramatically during the period, RS were shown to be associated with a greater risk of blood transfusion compared to bedside staplers both in a GLM [0.5% (BS) vs 0.7% (RS); Odds ratio (OR): 1.55; 95% confidence interval (CI): 1.02-2.36; p = 0.04] and after PSM [0.3% (BS) vs 0.9% (RS); OR: 3.02; 95% CI: 1.35-6.73; p = 0.007]. Bedside staplers were associated with total costs reduction [mean cost savings: $3084; 95% CI: $2860 - $3309; p < 0.001] and shorter ORT (21 minutes; 95% CI: 18.6-23.5; p < 0.001) compared to robotic staplers. Difference in LOS was not clinically significant.</p><p><strong>Conclusion: </strong>When used during RSG, bedside staplers are cost-saving, with equivalent or better clinical outcomes and reduced resource utilization compared to robotic staplers.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"17 ","pages":"561-569"},"PeriodicalIF":2.2,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12379977/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144973705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Burden and Costs of Anti-Neutrophil Cytoplasmic Antibody-ANCA-Associated Vasculitis: Main Findings from REDCap Registry of a University Hospital in Spain.","authors":"Juliana Draibe, Laura Martinez Valenzuela, Francisco Gomez-Preciado, Paula Anton-Pampols, Ana Melissa Rau, Helena Díaz-Cuervo, Carlos Crespo, Jesús Cuervo, Antonio Ramirez de Arellano","doi":"10.2147/CEOR.S529853","DOIUrl":"10.2147/CEOR.S529853","url":null,"abstract":"<p><strong>Purpose: </strong>Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) are rare chronic autoimmune diseases, potentially fatal, with frequent relapses. They are associated with vital organ damage, especially renal, often resulting in end-stage renal disease. While current standard of care with immunosuppressants has improved renal function and survival, the main risks for patients under life-long immunosuppression are infections and other concomitant diseases. This study evaluated the burden of AAV using patient-level data from a disease-specific registry.</p><p><strong>Patients and methods: </strong>The cohort of incident AVV patients (2013-2022) in the REDCap registry in a university hospital in Spain was studied. Patients with Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA) and Eosinophilic Granulomatosis with Polyangiitis (EGPA) with at least one year of follow-up (or deceased during the period) were included. Clinical outcomes, including Birmingham Vasculitis Activity Score (BVAS) and healthcare resource consumption were analysed for the first year after diagnosis. Mean annual costs were calculated using unitary costs from the hospital accounting department.</p><p><strong>Results: </strong>Seventy-five patients (12% EGPA, 32% GPA, and 56% MPA) were included. Fifty-two percent were women. Mean age at diagnosis was 65.20±14.70 years. At baseline, mean BVAS was 17.35±5.70, 93.33% of patients showed renal affectation, mean estimated glomerular filtration rate was 33.32±29.93mL/min/1.73m². As induction treatment, 62.67% received methylprednisolone, 37.33% rituximab, 25.33% cyclophosphamide, 14.67% rituximab plus cyclophosphamide, 34.67% plasmapheresis. During the first year after diagnosis, 17.33% relapsed and 78.67% had at least 1 hospitalisation; 97.33% received steroids; 13.33% were on dialysis at some point; one patient received a kidney transplant; 46.67% presented infections and 28% suffered corticosteroid-associated complications; 4 patients died, being 50% of deaths treatment-related. The highest observed mean cost per patient for the first year was €11,647.95 for hospital care.</p><p><strong>Conclusion: </strong>This study revealed a considerable burden of AAV, as evidenced by high rates of hospitalisation, relapses, and the need for intensive medical interventions.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"17 ","pages":"537-546"},"PeriodicalIF":2.2,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12323866/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144790381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma [Letter].","authors":"Niodita Gupta-Werner, Joseph Goble, Mary Slavcev","doi":"10.2147/CEOR.S550970","DOIUrl":"10.2147/CEOR.S550970","url":null,"abstract":"","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"17 ","pages":"535-536"},"PeriodicalIF":2.2,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12318513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144776540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-Utility Analysis of Metabolic Bariatric Surgery for Individuals with Obesity in Saudi Arabia.","authors":"Mouaddh Abdulmalik Nagi, Saowalak Turongkaravee, Ziyad Saeed Almalki, Montarat Thavorncharoensap, Sermsiri Sangroongruangsri, Usa Chaikledkaew, Abdulhadi M Alqahtani, Lamis S AlSharif, Ibrahim A Alsubaihi, Abdulaziz I Alzarea, Mohammed M Alsultan","doi":"10.2147/CEOR.S527169","DOIUrl":"10.2147/CEOR.S527169","url":null,"abstract":"<p><strong>Background: </strong>Metabolic bariatric surgery (MBS) is an effective and relatively safe intervention for managing obesity. This study aimed to evaluate the cost-utility of MBS compared with the standard treatment-lifestyle modification plus liraglutide-in the Kingdom of Saudi Arabia (KSA).</p><p><strong>Methods: </strong>A Markov model was developed to estimate the lifetime costs and outcomes of MBS. Costs and outcomes were discounted at an annual rate of 3%. The analysis was conducted from societal and healthcare system perspectives, using a willingness-to-pay (WTP) threshold of one to three times the gross domestic product (GDP) per capita per quality-adjusted life years (QALY) gained. Direct medical and nonmedical costs were obtained from hospital records and patient surveys, respectively. Transitional probabilities and utility values were obtained from published literature and primary data collection in the KSA. One-way and probabilistic sensitivity analyses were performed to assess parameter uncertainty.</p><p><strong>Results: </strong>Over a lifetime horizon, MBS yielded 0.38 incremental QALY and US$ 11,975 (Saudi Riyal [SAR] 44,905; purchasing power parity [PPP] 23,911) incremental costs, leading to an incremental cost-effectiveness ratio (ICER) of US$ 31,909 (SAR 119,660; PPP 63,717) per QALY gained from a societal perspective and US$ 36,353 (SAR 136,324); PPP 72,590) from a healthcare system perspective. The model was most sensitive to the discount rates of costs and outcomes and the direct medical costs associated with MBS. At a WTP threshold of one GDP per capita (US$ 30,436; SAR 114,135; PPP 60,775), the standard treatment had a 63% probability of being cost-effective. However, at a threshold of approximately 1.8 GDP per capita (US$ 56,000; SAR 210,000; PPP 111,821), MBS was cost-effective in 100% of the iterations.</p><p><strong>Conclusion: </strong>MBS is a cost-effective intervention compared with standard treatment in the context of the KSA. Efforts should be made to expand earlier and equitable access to MBS for individuals with a BMI > 40 kg/m² without comorbidities across the country.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"17 ","pages":"519-533"},"PeriodicalIF":2.2,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12301112/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144733862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing Patient Safety and Charge Capture Through Smart Infusion Pump Interoperability: A Health Economic Analysis for US Health Systems.","authors":"Eric P Borrelli, Ashley Taneja, Shafiq Abdallah, Mia Weiss, Nicole S Wilson, Idal Beer, Julia D Lucaci","doi":"10.2147/CEOR.S534748","DOIUrl":"10.2147/CEOR.S534748","url":null,"abstract":"<p><strong>Purpose: </strong>To estimate the economic impact of implementing smart infusion pump interoperability for a hypothetical health system in the United States (US).</p><p><strong>Patients and methods: </strong>An economic model was developed to assess the financial impact of implementing smart infusion pump interoperability with electronic health records (EHRs) for a health system. The model perspective was that of a moderately-large hypothetical US heath-system consisting of 6 hospitals, with 1,500 staffed beds and 50,000 discharges annually. The main outcomes of interest in this model were patient safety and outpatient intravenous (IV) administration charge capture. The impact of interoperability on patient safety was assessed by measuring the estimated reduction in preventable adverse drug events (pADEs). The impact on outpatient charge capture was assessed by estimating the reduction in lost charges due to the implementation of interoperability. All model parameters and inputs were derived and supported by peer-reviewed literature.</p><p><strong>Results: </strong>In the base-case analysis, the implementation of smart infusion pump interoperability resulted in an annual reduction of 56 pADEs, saving the health system $531,891 in associated pADE treatment costs. This equates to a total reduction of 281 pADEs over the 5-year time-horizon, with a cumulative cost savings of $2,659,457. Additionally, the implementation of interoperability recouped $2,419,673 in outpatient infusion administration charges annually, which is equivalent to $12,098,363 in recouped charges over five years.</p><p><strong>Conclusion: </strong>The implementation of smart infusion pump interoperability has the potential to enhance patient safety by reducing pADEs and improving outpatient administration charge capture. However, it is important to note that while the model is based on peer-reviewed model inputs, the model itself is theoretical in nature without real-world data validation and does not account for investment costs. Health systems should carefully evaluate the safety and economic implications of smart infusion pump interoperability when deciding whether to invest in this technology.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"17 ","pages":"507-518"},"PeriodicalIF":2.2,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12301143/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144733863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Healthcare Costs and Treatment Patterns of Triplet Therapies in Relapsed/Refractory Multiple Myeloma: Real World Evidence from Italy.","authors":"Valentina Perrone, Melania Leogrande, Elisa Giacomini, Maria Cappuccilli, Luca Degli Esposti","doi":"10.2147/CEOR.S529788","DOIUrl":"10.2147/CEOR.S529788","url":null,"abstract":"<p><strong>Purpose: </strong>This analysis sought to characterize patients with relapsed or refractory multiple myeloma (RRMM) on triplet therapy with immunomodulatory agents/proteasome inhibitors/monoclonal antibodies combined with dexamethasone, describing their demographic and clinical features, therapeutic pathways and the related healthcare costs for the Italian National Health Service (NHS).</p><p><strong>Patients and methods: </strong>A retrospective observational analysis was conducted on administrative databases of Italian healthcare entities, covering about 3.6 million health-assisted residents. From 2017 to 2020, patients receiving at least one triplet combination reimbursed by the Italian NHS for the treatment of RRMM were included. RRMM treatment pathways were evaluated in terms of duration of therapy and treatment lines. Healthcare costs per patient were assessed on monthly basis during the therapy period by computing expenditures for drugs, hospitalizations and outpatient specialist services.</p><p><strong>Results: </strong>A total of 209 RRMM patients on triplet combinations were identified, with a mean age of 67.4 years, 56% males and mild-to-moderate comorbidity profile, with heart disease and renal disease as the most common coexisting conditions (respectively, 13.4% and 7.7% of patients). KRd (carfilzomib/lenalidomide/dexamethasone) was the triplet administrated to the largest proportion of patients (44%), then DaraRd (daratumumab/lenalidomide/dexamethasone) triplet (24%). Treatment duration was on average 7 months for overall patients, 7.7 months for 118 patients with triplet as second line at inclusion, and 6 months for 91 patients with triplet as third or further line at inclusion. The monthly overall costs were € 9,517, with drug expenses accounting for 93% of total expenditures. Progressing to later treatment lines, cost analysis showed comparable trends, being drugs as the most impactive item.</p><p><strong>Conclusion: </strong>This analysis on RRMM patients under triplet medication in real-life Italian clinical practice confirmed the complex multifaceted profile of this frail population, highlighting a challenging clinical management for the oncologists and a major economic burden for the NHS.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"17 ","pages":"495-505"},"PeriodicalIF":2.1,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12285882/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144700081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adding Tolvaptan in the Inpatient Treatment for Patients with Heart Failure and Hyponatremia: Budget Impact Analysis in Thailand.","authors":"Unchalee Permsuwan, Krit Leemasawat, Poukwan Arunmanakul","doi":"10.2147/CEOR.S503735","DOIUrl":"10.2147/CEOR.S503735","url":null,"abstract":"<p><strong>Objective: </strong>Tolvaptan is used as an add-on therapy for heart failure (HF) patients with volume overload, particularly those with hyponatremia (HN), but its cost raises concern. This study aimed to estimate the budget impact of adding 30 mg of tolvaptan to standard treatment compared to standard treatment alone in hospitalized HF patients with HN in Thailand.</p><p><strong>Methods: </strong>A budget impact analysis (BIA) model was developed in accordance with Thai Health Technology Assessment guidelines from the payer's perspective. Epidemiological data on HF in Thailand were used to estimate the target population. Clinical effectiveness data were derived from the EVEREST trial. Cost components included tolvaptan acquisition and HF-related hospitalization costs. Cost data were sourced from the National Health Security Office. The net budget impact (NBI) was calculated as the difference in total budget between standard care with tolvaptan and standard care alone. Deterministic sensitivity analysis was performed to explore the impact of key variables.</p><p><strong>Results: </strong>The total budget without tolvaptan was 201 million THB (5,802,973 USD), increasing to 221 million THB (6,365,607 USD) with tolvaptan, resulting in an NBI of 19.5 million THB (562,634 USD) or 1117 THB (32 USD) per member. Despite higher drug costs, tolvaptan use reduced hospitalization costs (4.2 million USD vs 5.8 million USD) due to fewer HF hospitalization days and length of stay reduction. A lower tolvaptan dose, reduced HN risk, or a daily cost reduction of at least 25.5% could result in a negative NBI.</p><p><strong>Conclusion: </strong>Although tolvaptan reduced hospital length of stay, its use at 30 mg daily still led to a positive NBI. These findings are relevant for Thailand and similar healthcare systems considering tolvaptan adoption.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"17 ","pages":"485-494"},"PeriodicalIF":2.1,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12276736/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144676156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the Economic Impact of Diabetes Mellitus: A Hospital-Centric Cost Analysis in Hail, Saudi Arabia.","authors":"Abdullah Mohammad Alshammari, Mohamed Hassan Elnaem, Siew Chin Ong","doi":"10.2147/CEOR.S521701","DOIUrl":"10.2147/CEOR.S521701","url":null,"abstract":"<p><strong>Background: </strong>Diabetes mellitus (DM) is a chronic non-communicable disease (NCD) that imposes a significant economic burden on healthcare systems and households. This study aimed to estimate the direct medical costs associated with diabetes care from a hospital perspective in Hail, Saudi Arabia.</p><p><strong>Methods: </strong>A retrospective, hospital-based study was conducted using data from hospital records of diabetic patients treated at King Khalid Hospital (KKH) and King Salman Specialized Hospital (KSSH) in Hail. The study employed a top-down approach to estimate direct medical costs, including consultation, lab tests, medications, admissions, and annual check-ups. Costs were adjusted to US dollars (1 USD = 3.75 SAR). Ethical approval was obtained from the Hail Health Cluster (IRB Log Number: 2023-44).</p><p><strong>Results: </strong>A total of 377 diabetic patients were included in the study. The mean age was 58.02 years (SD = 18.80), with 53.3% male and 46.7% female patients. The average total annual cost per patient was US$6689.1 (±3450.1), with admission costs being the highest contributor (US$2686.0 ± 3373.0). The total estimated cost for all patients combined was approximately US$2.52 million. Older age, female gender, DM complications, and treatment at KSSH were significantly associated with higher direct costs.</p><p><strong>Conclusion: </strong>The economic burden of diabetes is substantial and continues to rise annually. Policymakers should prioritize cost-effective interventions and improve data collection across hospitals to better understand and mitigate the financial impact of diabetes.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"17 ","pages":"473-484"},"PeriodicalIF":2.1,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12275922/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144676157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Cost Analysis for Direct Medical Costs of Protocol Administration of Non-Small Cell Lung Cancer Treatment Regimens in Curative Intent: A Micro-Costing Study in Jordan.","authors":"Saba S Madae'en, Ahmed A Salem, Naila S Ararawi, Ezaldeen J Ramzi, Roa'a F Aloueedat, Abdullah M Saabenh, Diala A Allouzi, Reem H Abuoudeh, Osama E Hnaif, Leen M Musa, Salma H Alshdaifat, Ahmad J Al-Tanashat, Hala Y Almasa'afeh, Salma M Abuallaban","doi":"10.2147/CEOR.S520119","DOIUrl":"10.2147/CEOR.S520119","url":null,"abstract":"<p><strong>Background: </strong>Non-small cell lung cancer (NSCLC) treatment costs significantly impact healthcare systems. This study analyzes direct costs and cost drivers of perioperative and adjuvant systemic treatments for stage I-II NSCLC from Jordanian healthcare providers' perspective using micro-costing methodology.</p><p><strong>Methods: </strong>We employed micro-costing to analyze direct medical expenses including drug acquisition, preparation, administration, pre/post-medications, diagnostics, labor, and wastage costs for perioperative regimens used in stage I-II NSCLC. International guidelines defined therapeutic regimens, while drug prices were extracted from Jordan Food and Drug Administration's database. Published data and surveys quantified micro-costs.</p><p><strong>Results: </strong>Among 26 assessed regimens (2 targeted therapy, 10 chemotherapy, 10 chemo-immunotherapy, 4 immunotherapy), targeted/immunotherapy agents significantly increased costs. Chemotherapy regimen cost differences ranged from $633.68 (squamous) to $1,763.91 (non-squamous) per cycle. Antineoplastic agents were primary cost drivers, highest for Durvalumab (98.72% of cycle cost). Laboratory costs comprised up to 50.73% in chemotherapy and 7.24% in immunotherapy regimens. Wastage contributed up to 10.36% of total cycle costs. Average administration cost was $35 per cycle. Maximum cycle costs were: targeted therapy (Osimertinib) $7,206.44, immunotherapy (Durvalumab) $9,057.71, immune-chemotherapy (Durvalumab-Carboplatin-Pemetrexed) $11,358.43, and chemotherapy (Carboplatin-Pemetrexed) $2,300.72.</p><p><strong>Conclusion: </strong>Our results highlight the substantial economic impact and cost variability among treatment regimens. This variability presents opportunities for cost reduction through careful selection of therapeutically equivalent regimens based on pricing and toxicity profiles. The findings emphasize the need for comprehensive and precise cost analysis to inform healthcare policies and clinical practices. Future research should focus on cost-effectiveness analyses of these expensive agents to ensure value for money, support evidence-based decision-making, and strengthen price negotiations with suppliers.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"17 ","pages":"455-471"},"PeriodicalIF":2.1,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12267825/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144660756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}